Chi Meng Fong
Stock Analyst at Bank of America Securities
(2.04)
# 3,286
Out of 4,609 analysts
40
Total ratings
44.4%
Success rate
3.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chi Meng Fong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Reiterated: Hold | $32 → $35 | $35.12 | -0.34% | 25 | Jul 31, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $63 | $46.76 | +34.73% | 1 | Jul 13, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $21 | $19.75 | +6.33% | 4 | Jun 2, 2026 | |
| CCCC C4 Therapeutics | Rated: Hold | n/a | $3.64 | n/a | 5 | Oct 31, 2023 | |
| FHTX Foghorn Therapeutics | Rated: Hold | n/a | $5.57 | n/a | 5 | Oct 6, 2023 |
Roivant Sciences
Jul 31, 2026
Reiterated: Hold
Price Target: $32 → $35
Current: $35.12
Upside: -0.34%
Supernus Pharmaceuticals
Jul 13, 2026
Maintained: Buy
Price Target: $63
Current: $46.76
Upside: +34.73%
Relay Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $21
Current: $19.75
Upside: +6.33%
C4 Therapeutics
Oct 31, 2023
Rated: Hold
Price Target: n/a
Current: $3.64
Upside: n/a
Foghorn Therapeutics
Oct 6, 2023
Rated: Hold
Price Target: n/a
Current: $5.57
Upside: n/a